bi 765049
mAbexperimentalBi-specific
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started May 12, 2021 (NCT04752215)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
CD3E
- Pseudomonas aeruginosaBINDING AGENT
Pseudomonas aeruginosa binding agent
Chemistry & pharmacology
- Multi-specific
- Yes (Bi-specific)
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06882746 | Phase 1 | Mar 28, 2025 | Boehringer Ingelheim |
| NCT06091930 | Phase 1 | Jan 15, 2024 | Boehringer Ingelheim |
| NCT04752215 | Phase 1 | May 12, 2021 | Boehringer Ingelheim |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Boehringer Ingelheim | For profit | 3 | 3 | 1 | 2021 |
1 organizations
Page 1 / 1